Literature DB >> 21513757

Behçet's disease exhibits an increased osteopontin serum level in active stage but no association with osteopontin and its receptor gene polymorphisms.

Mingliang Chu1, Peizeng Yang, Shengping Hou, Fuzhen Li, Yuanyuan Chen, Aize Kijlstra.   

Abstract

Osteopontin (OPN) and its receptors have been reported to be involved in a number of autoimmune and inflammatory diseases. This study was designed to analyze the OPN serum level in Behçet's disease (BD) and the association of gene polymorphisms of OPN and its receptors with BD. The serum level of OPN in active BD patients, inactive BD patients, and controls was assayed by enzyme-linked immunosorbent assay. Four single nucleotide polymorphisms (SNPs) of OPN and 4 SNPs of OPN receptors were genotyped in 318 BD patients and 313 controls using a polymerase chain reaction restriction fragment length polymorphism assay. The OPN level was significantly increased in the serum of active BD patients compared with inactive BD patients and controls. SNP analysis indicated an increased frequency of the OPN rs1126772 A allele in BD patients compared with controls. However, the significance was lost after Bonferroni correction. The prevalence of other SNPs of OPN and its receptors did not differ between BD patients and controls. The results suggest that an increased serum OPN level was associated with clinical severity of BD. There was no association of the tested SNPs of OPN and its receptors with BD in Chinese Han patients.
Copyright © 2011 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21513757     DOI: 10.1016/j.humimm.2011.03.016

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  9 in total

Review 1.  The genetics of Behçet's disease in a Chinese population.

Authors:  Shengping Hou; Aize Kijlstra; Peizeng Yang
Journal:  Front Med       Date:  2012-11-15       Impact factor: 4.592

Review 2.  Outcome measures used in clinical trials for Behçet syndrome: a systematic review.

Authors:  Gulen Hatemi; Peter A Merkel; Vedat Hamuryudan; Maarten Boers; Haner Direskeneli; Sibel Z Aydin; Hasan Yazici
Journal:  J Rheumatol       Date:  2014-02-01       Impact factor: 4.666

3.  The Immunogenetics of Cutaneous Drug Reactions.

Authors:  Neda Khalili
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

4.  Soluble levels of osteopontin in patients with Behcet's disease: association with disease activity and vascular involvement.

Authors:  Iman H Bassyouni; Mohammed M El-Wakd; Rasha H Bassyouni
Journal:  J Clin Immunol       Date:  2012-10-25       Impact factor: 8.317

5.  Association of osteopontin polymorphism with cancer risk: a meta-analysis.

Authors:  Gang Yang; Xiaoxing Peng; Pengju Guo; Ge Yang
Journal:  Int J Clin Exp Med       Date:  2015-11-15

6.  Serum osteopontin, but not OPN gene polymorphism, is associated with LVH in essential hypertensive patients.

Authors:  Xuwei Hou; Zhaohui Hu; Xiaohua Huang; Yan Chen; Xiuying He; Haiying Xu; Ningfu Wang
Journal:  J Mol Med (Berl)       Date:  2013-12-27       Impact factor: 4.599

7.  The association between osteopontin gene polymorphisms, osteopontin expression and sarcoidosis.

Authors:  Hadas Lavi; Miri Assayag; Assaf Schwartz; Nissim Arish; Zvi G Fridlender; Neville Berkman
Journal:  PLoS One       Date:  2017-03-02       Impact factor: 3.240

Review 8.  Osteopontin Bridging Innate and Adaptive Immunity in Autoimmune Diseases.

Authors:  Nausicaa Clemente; Davide Raineri; Giuseppe Cappellano; Elena Boggio; Francesco Favero; Maria Felicia Soluri; Chiara Dianzani; Cristoforo Comi; Umberto Dianzani; Annalisa Chiocchetti
Journal:  J Immunol Res       Date:  2016-12-20       Impact factor: 4.818

9.  Investigation of osteopontin levels and genomic variation of osteopontin and its receptors in Type 1 diabetes mellitus.

Authors:  Z Karamizadeh; E Kamali Sarvestani; F Saki; H Karamifar; G H Amirhakimi; M H Namavar Shooshtarian; S Ashkani-Esfahani
Journal:  J Endocrinol Invest       Date:  2013-09-27       Impact factor: 5.467

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.